Evaluation of liver stiffness measurement–based scores in liver transplantation recipients

Combining bioclinical parameters with liver stiffness measurement (LSM) has improved the diagnostic performance of vibration‐controlled transient elastography (VCTE) for detection of advanced fibrosis in patients with chronic liver disease. However, this approach has not yet been tested in liver transplantation (LT) recipients. Thus, the aim of this study was to evaluate the diagnostic performance of combining LSM‐based scores with LSM alone for the detection of advanced fibrosis in LT recipients. Adult LT recipients with a liver biopsy, VCTE, and clinical data necessary to construct LSM‐based fibrosis models (FibroScan‐AST [FAST], AGILE‐3+, and AGILE‐4) were included (n = 132). The diagnostic statistics for advanced fibrosis (fibrosis stage 0–2 vs. 3–4) were determined by optimal cut‐off using the Youden index. The area under the receiver operating characteristic curve (AUROC) for LSM was 0.94 (95% confidence interval [95% CI], 0.89–0.99), FAST was 0.65 (95% CI, 0.50–0.79), AGILE‐3+ was 0.90 (95% CI, 0.83–0.97), and AGILE‐4 was 0.90 (95% CI, 0.83–0.97). No statistically significant differences were noted between the AUROC of LSM versus LSM‐based scores. The false‐positive rates for AGILE‐3+ and AGILE‐4 were 14.5% and 11.8% compared with 8.3% for LSM alone. The false‐positive rates in LSM‐based scores were higher among patients with diabetes mellitus, higher AST levels, and lower platelet counts. The LSM‐based scores did not improve the diagnostic performance of LSM alone in LT recipients for the detection of advanced fibrosis. This lack of improvement in diagnostic performance results from the impact of immunosuppression on bioclinical profile and underscores the importance of developing LSM‐based scores that are specific to LT patients.